retatrutide injection frequency How to inject retatrutide: complete step-by-step guide ESC 2024: Retatrutide improves lipid

Phase 3 trial completion timeline Seven Phase 3 trials are expected to report results during this year

It was later approved in November 2023 as Zepbound for obesity treatment

Loss of muscle mass is closely linked to reduced mobility and strength, increased risk of frailty, and slower recovery from illness or injury

Wash your hands thoroughly with soap and water

Known and theoretical safety concerns include: Retatrutide (and the GLP-1 receptor agonist class): Nausea, vomiting, diarrhoea, and reduced appetite are the most commonly reported side effects

In these studies, rats and mice treated with GLP-1 medications developed C-cell tumors in the thyroid gland, a type of tumor that can develop into medullary thyroid carcinoma (MTC)